Bladder, Breast, Colorectal Cancer, and Melanoma- Treatment Summary Table
Only one measure per topic is displayed in the summary table. A complete set of measures, where they exist, can be found by following the More Information link in the table below.
![]() |
green - headed in the right direction |
![]() |
red - headed in the wrong direction |
![]() |
black - stable or non-significant change (NSC) |
![]() |
purple - indeterminate |
![]() |
blue - Healthy People 2030 target |
Measure Name | Bladder Cancer Treatment | Breast Cancer Treatment | Colorectal Cancer Treatment | Melanoma of the Skin Treatment |
---|---|---|---|---|
Year Range | 1995-2019 | 1987-2015 | 1987-2015 | 2001-2018 |
Measure |
Percentage of individuals receiving intravesical therapy. Percentage of individuals receiving systemic therapy. |
Percentage of women aged 20 and older, diagnosed with early stage breast cancer (stage I or II), receiving breast-conserving surgery and radiation treatment. Percentage of women aged 20 and older, diagnosed with node-positive, stage I–IIIA breast cancer, receiving multi-agent chemotherapy. Note: This measure includes women with both hormone receptor positive and negative breast cancer. |
Percent of individuals, aged 20 years and older, diagnosed with stage III colon cancer who received adjuvant chemotherapy or diagnosed with stage II or stage III rectal cancer who received chemotherapy with or without radiation therapy. |
Percentage of individuals with advanced (stage III or IV) melanoma of the skin receiving chemotherapy. |
Recent Summary Trend | Non-Significant Change | Stable | Rising | Rising |
Recent Summary Trend Year Range | 2009-2019 | 2010-2015 | 2010-2015 | 2011-2018 |
Desired Direction | Rising | Rising | Rising | Rising |
Summary Graph |
![]() |
![]() |
![]() |
![]() |
Trends and Most Recent Estimates | In 2019, 35.5% of patients with non-muscle invasive disease received intravesical therapy. | In 2015, 64.2% of women diagnosed with node positive breast cancer, received multi-agent chemotherapy. | In 2015, 70.3% of stage III colon and stage II and III rectal patients received adjuvant chemotherapy. | In 2018, 79.4% of stage III or IV melanoma of the skin patients aged 20 years and older received chemotherapy. |
Healthy People 2030 Target | No Healthy People Target for this measure. | No Healthy People Target for this measure. | No Healthy People Target for this measure. | No Healthy People Target for this measure. |
More Information | Bladder Cancer Treatment | Breast Cancer Treatment | Colorectal Cancer Treatment | Melanoma of the Skin Treatment |
Last Updated | August 2023 | August 2023 | August 2023 | August 2023 |
Measure Name | Melanoma of the Skin Treatment |
---|---|
Year Range | 2001-2018 |
Measure |
Percentage of individuals with advanced (stage III or IV) melanoma of the skin receiving chemotherapy. |
Recent Summary Trend | Rising |
Recent Summary Trend Year Range | 2011-2018 |
Desired Direction | Rising |
Summary Graph |
![]() |
Trends and Most Recent Estimates | In 2018, 79.4% of stage III or IV melanoma of the skin patients aged 20 years and older received chemotherapy. |
Healthy People 2020 Target | No Healthy People Target for this measure. |
More Information | Melanoma of the Skin Treatment |
Measure Name | Breast Cancer Treatment |
---|---|
Year Range | 1987-2015 |
Measure |
Percentage of women aged 20 and older, diagnosed with early stage breast cancer (stage I or II), receiving breast-conserving surgery and radiation treatment. Percentage of women aged 20 and older, diagnosed with node-positive, stage I–IIIA breast cancer, receiving multi-agent chemotherapy. Note: This measure includes women with both hormone receptor positive and negative breast cancer. |
Recent Summary Trend | Stable |
Recent Summary Trend Year Range | 2010-2015 |
Desired Direction | Rising |
Summary Graph |
![]() |
Trends and Most Recent Estimates | In 2015, 64.2% of women diagnosed with node positive breast cancer, received multi-agent chemotherapy. |
Healthy People 2020 Target | No Healthy People Target for this measure. |
More Information | Breast Cancer Treatment |
Measure Name | Bladder Cancer Treatment |
---|---|
Year Range | 1995-2019 |
Measure |
Percentage of individuals receiving intravesical therapy. Percentage of individuals receiving systemic therapy. |
Recent Summary Trend | Non-Significant Change |
Recent Summary Trend Year Range | 2009-2019 |
Desired Direction | Rising |
Summary Graph |
![]() |
Trends and Most Recent Estimates | In 2019, 35.5% of patients with non-muscle invasive disease received intravesical therapy. |
Healthy People 2020 Target | No Healthy People Target for this measure. |
More Information | Bladder Cancer Treatment |
Measure Name | Colorectal Cancer Treatment |
---|---|
Year Range | 1987-2015 |
Measure |
Percent of individuals, aged 20 years and older, diagnosed with stage III colon cancer who received adjuvant chemotherapy or diagnosed with stage II or stage III rectal cancer who received chemotherapy with or without radiation therapy. |
Recent Summary Trend | Rising |
Recent Summary Trend Year Range | 2010-2015 |
Desired Direction | Rising |
Summary Graph |
![]() |
Trends and Most Recent Estimates | In 2015, 70.3% of stage III colon and stage II and III rectal patients received adjuvant chemotherapy. |
Healthy People 2020 Target | No Healthy People Target for this measure. |
More Information | Colorectal Cancer Treatment |